United States · FDA National Drug Code directory
Cemiplimab
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 61434-021_3c2f43ff-ae03-5276-e063-6294a90a6143
- Product NDC
- 61434-021
- Form
- INJECTION
- Composition / generic term
- Cemiplimab
- Labeler
- Catalent Indiana, LLC
- Marketing category
- DRUG FOR FURTHER PROCESSING
- Marketing start / end (source format)
- 20180928
- Source listing expiry
- 20261231
Source-listed ingredients
- CEMIPLIMAB — 350 mg/7mL
These values do not establish equivalence or a dose recommendation.
Packages
- 384 VIAL in 1 CASE (61434-021-02) / 7 mL in 1 VIAL · 61434-021-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →